We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Daiichi Sankyo Company Ltd (PK) | USOTC:DSNKY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.515 | 1.47% | 35.495 | 35.45 | 35.54 | 35.60 | 35.38 | 35.58 | 86,802 | 21:29:17 |
From May 2023 to May 2024
By Anthony O. Goriainoff
AstraZeneca and Daiichi Sankyo said that datopotamab deruxtecan, a cancer drug, combined with the Imfinzi cancer treatment--with or without chemotherapy--showed disease control rates of 92% and 93% respectively in patients with previously untreated advanced or metastatic non-small cell lung cancer.
The Anglo-Swedish pharma giant said Monday that the results reinforced its confidence in this being a potential treatment option for patients with this type of lung cancer.
"Three ongoing pivotal trials are evaluating datopotamab deruxtecan and immune checkpoint inhibitor combinations in first-line advanced non-small cell lung cancer," AstraZeneca said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 11, 2023 02:40 ET (06:40 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Daiichi Sankyo (PK) Chart |
1 Month Daiichi Sankyo (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
